Hiroaki Asai

CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Daisuke Ennishi, Kengo Takeuchi, Masaru Yokoyama et al. · Annals of Oncology · 2008 · 99 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +11

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

Daisuke Ennishi, Masaru Yokoyama, Y. Terui et al. · Annals of Oncology · 2008 · 59 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor

Hiroaki Asai, Hiroshi Fujiwara, Jun An et al. · PLoS ONE · 2013 · 47 citations · Full text

Gene-Modified Human α/β-T Cells Expressing a Chimeric CD16-CD3ζ Receptor as Adoptively Transferable Effector Cells for Anticancer Monoclonal Antibody Therapy

Fumihiro Ochi, Hiroshi Fujiwara, Kazushi Tanimoto et al. · Cancer Immunology Research · 2014 · 45 citations · Full text

Development of a novel redirected T-cell–based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia

Yukihiro Miyazaki, Hiroshi Fujiwara, Hiroaki Asai et al. · Blood · 2013 · 40 citations · Full text